Upadacitinib therapy as a successful treatment of severe atopic dermatitis in a patient with a previous dupilumab-induced exanthematous drug reaction
, 1, 1, 2, 1
Streszczenie
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory diseases.
Recently, new therapeutic options for patients with moderate-to-severe AD have
emerged, such as dupilumab or janus kinase inhibitors. This paper presents the case of
a patient who developed a rare exanthematous skin adverse reaction after the administration
of the initial dose of dupilumab.
Aim of the study: To showcase new therapeutic alternatives for patients with moderate-to-
-severe AD, such as dupilumab or Janus kinase inhibitors.
Material and methods: A retrospective review of the procedure and patient follow-up was
undertaken. Case report: A 43-year-old female with severe atopic dermatitis, was admitted
to the Department of Dermatology. The patient presented with severe erythematous lesions
on the lateral surfaces of the trunk, and upper and lower extremities, accompanied by
intense pruritis, which appeared 24 hours after starting dupilumab treatment. Because of
the suspicion of adverse drug reaction further treatment with dupilumab was suspended.
Improvement of skin lesions was observed within a few days. Due to persistent symptoms
of severe AD patient was qualified for upadacitinib - Janus kinase 1 inhibitor (JAK-1) with
a highly successful clinical response and continued treatment without any adverse events.
Conclusions: The take-home message is that even a relatively safe biologic therapy can
cause the occurrence of undesirable symptoms.
Słowa kluczowe: atopic dermatitisdupilumabJAK inhibitorexanthematous skin adverse reactionadverse drug reaction
Referencje
- Wood H, Chandler A, Nezamololama N, et al. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022; 61(6): 746–754.
- Torres T, Ferreira EO, Gonçalo M, et al. Update on Atopic Dermatitis. Acta Med Port. 2019; 32(9): 606–613.
- Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019; 40(2): 84–92.
- Yaşar G, Bilgiç A, Yılmaz E. Dupilumab for atopic dermatitis treatment: A single-center retrospective study. TURKDERM. 2022; 56(1): 12–16.
- Chun PI, Lehman H. Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis. Clin Rev Allergy Immunol. 2020; 59(2): 208–219.
- Albader SS, Alharbi AA, Alenezi RF, et al. Dupilumab side effect in a patient with atopic dermatitis: A case report study. Biologics. 2019; 13: 79–82.
- Ratchataswan T, Banzon TM, Thyssen JP, et al. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. J Allergy Clin Immunol Pract. 2021; 9(3): 1053–1065.
- Zabel M, Hile GA, Shefler A, et al. Dupilumab-induced pityriasis rosea. JAAD Case Rep. 2023; 33: 27–29.
- Wu L, Ali K, Qiu Y, et al. Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis. Acta Derm Venereol. 2022; 102: adv00743.
- Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report. JAAD Case Rep. 2019; 5(1): 34–36.
- Nahum Y, Mimouni M, Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020; 104(6): 776–779.
- Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022; 86(3): 628–636.
- Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021; 148(4): 927–940.
- Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31(1): 33–40.
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021; 157(9): 1047–1055.
